Localization of aromatase and 5α-reductase to neuronal and non-neuronal cells in the fetal rat hypothalamus

J. Canick,D. Vaccaro,Elizabeth M. Livingston,S. Leeman,K. Ryan,T. O. Fox

DOI: https://doi.org/10.1016/0006-8993(86)91135-2

IF: 3.61

1986-05-07

Brain Research

Abstract:

What problem does this paper attempt to address?

Fc Gamma Riiia Negatively Impacts Humoral Immune Responses But Not Overall Lung Inflammation In An Ovalbumin-Induced Allergic Asthma Mouse Model

Pingping Zhou,Tongqian Wu,Xiaoqian Jin,Jing Li,Haijian Yan,Ling Zhou,Yali Huang,Jun Wang,Haiyan Zhou,Xiaoping Zhu,Xiang Zou,Yu Fang

DOI: https://doi.org/10.1159/000487539

2018-01-01

International Archives of Allergy and Immunology

Abstract:Background: Fc gamma receptors (Fc gamma R) play substantial immune regulatory roles both positively and negatively in pathophysiological processes including allergy and asthma. Compared with Fc gamma RIIB which is classically defined as an inhibitory receptor, mouse Fc gamma RIIIA and its functional human homologue Fc gamma RIIA have been assumed to be activating receptors. However, evidence demonstrating inhibitory regulation by mouse Fc gamma RIIIA has recently been emerging. Objective: To dissect the contributory roles of mouse Fc gamma RIIIA (human Fc gamma RIIA) in parallel with Fc gamma RIIB in an ovalbumin (OVA)-induced mouse model of asthma and to preliminarily assess the correlation of the respective Fc gamma R with circulating IgE levels in human asthma patients. Methods: Wild-type, Fc gamma RIIB-/-, and Fc gamma RIIIA(-/-) mice were used in an OVA-induced asthma model followed by assessment of the allergic pathology focused on the lung tissues. Expression levels of Fc gamma RIIB, Fc gamma RIIA, and Fc gamma RIIIA on peripheral blood mononuclear cells (PBMC) together with the circulating IgE levels in the serum from patients with allergic asthma were analysed. Results: Although enhanced humoral immune responses typically represented by augmented OVA-specific IgG and IgE levels in serum were observed in the absence of Fc gamma RIIIA in the mouse asthma model, no overall regulation by Fc gamma RIIIA, especially in terms of those parameters measuring lung tissue inflammation, was recorded. As expected, in the absence of Fc gamma RIIB, augmented immune responses measured as serum antibody levels as well as those in various regulatory pathways in this mouse asthma model were observed. The expression levels of human Fc gamma RIIB but not Fc gamma RIIA were negatively correlated with serum levels of IgE in human asthma patients. Conclusion: We did not find major evidence demonstrating an immune inhibitory role of mouse Fc gamma RIIIA in this OVA-induced mouse asthma model. As asthma is a complex disease and the immune regulatory responses involve sophisticated components and pathways, the exact roles of Fc gamma RIIIA as well as its human functional homologue Fc gamma RIIA in asthma still await further clarification using other mouse asthma models as well as clinical studies. (C) 2018 S. Karger AG, Basel.
Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Yan Wei,Zhili Zhang,Feng Wang,Shuihong Zhou

DOI: https://doi.org/10.3892/etm.2017.5501

IF: 2.7

2017-01-01

Experimental and Therapeutic Medicine

Abstract:To identify a novel and effective therapy for allergic rhinitis and asthma (ARA), the present study focused on treatment with tumor growth factor (TGF)-β1 neutralizing antibody. In the present study, four medications were administered to mice with ovalbumin-induced allergic inflammation. Allergic symptoms in the lungs and nasal mucosa were evaluated by detecting the secretion of cytokines from helper T cells (Th) in the peripheral blood, nasal lavage fluid and bronchoalveolar lavage fluid using ELISA. Defects in regulatory T (Treg) cells in peripheral blood mononuclear cells were also detected using flow cytometry. Furthermore, the expression of TGF-β1 and activation of Smad2/3 pathways were assessed using immunohistochemical staining, reverse transcription-quantitative polymerase chain reaction, and western blotting. It was observed that TGF-β1 neutralizing antibody inhibited symptoms of inflammation in the upper and lower airways. TGF-β1 neutralizing antibody also restored the Th1/Th2 balance and ameliorated Treg cell defects induced by ARA. Furthermore, the therapeutic effects of TGF-β1 neutralizing antibody were related to its inhibitory effects on TGF-β1 expression and Smad2/3 signaling in nasal and lung tissues. Therefore, TGF-β1 neutralizing antibody may be an effective medicine for the treatment of ARA.
Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma

Jian-wen Di,Yi-xin Wang,Rui-xue Ma,Zhi-jie Luo,Wen-ting Chen,Wan-mei Liu,Ding-yi Yuan,Yu-ying Zhang,Yin-hao Wu,Cai-ping Chen,Jun Liu

DOI: https://doi.org/10.1007/s10565-024-09852-x

2024-02-11

Cell Biology and Toxicology

Abstract:V-type immunoglobulin domain–containing suppressor of T-cell activation (VISTA), a novel negative checkpoint regulator, plays an essential role in allergic pulmonary inflammation in mice. Treatment with a VISTA agonistic antibody could significantly improve asthma symptoms. Thus, for allergic asthma treatment, VISTA targeting may be a compelling approach. In this study, we examined the functional mechanism of VISTA in allergic pulmonary inflammation and screened the FDA-approved drugs for VISTA agonists. By using mass cytometry (CyTOF), we found that VISTA deficiency primarily increased lung macrophage infiltration in the OVA-induced asthma model, accompanied by an increased proportion of M1 macrophages (CD11b + F4/80 + CD86 + ) and a decreased proportion of M2 macrophages (CD11b + F4/80 + CD206 + ). Further in vitro studies showed that VISTA deficiency promoted M1 polarization and inhibited M2 polarization of bone marrow–derived macrophages (BMDMs). Importantly, we discovered baloxavir marboxil (BXM) as a VISTA agonist by virtual screening of FDA-approved drugs. The surface plasmon resonance (SPR) assays revealed that BXM (KD = 1.07 μM) as well as its active form, baloxavir acid (BXA) (KD = 0.21 μM), could directly bind to VISTA with high affinity. Notably, treatment with BXM significantly ameliorated asthma symptoms, including less lung inflammation, mucus secretion, and the generation of Th2 cytokines (IL-5, IL-13, and IL-4), which were dramatically attenuated by anti-VISTA monoclonal antibody treatment. BXM administration also reduced the pulmonary infiltration of M1 macrophages and raised M2 macrophages. Collectively, our study indicates that VISTA regulates pulmonary inflammation in allergic asthma by regulating macrophage polarization and baloxavir marboxil, and an old drug might be a new treatment for allergic asthma through targeting VISTA.

cell biology,toxicology
Enhanced Local Foxp3 Expression in Lung Tissue Attenuates Airway Inflammation in A Mouse Model of Asthma

Min Zhang,Ying-Ying Qian,Shou-Jie Chai,Zu-Yu Liang,Qian Xu,Zu-Qun Wu,Kai Wang

DOI: https://doi.org/10.3109/02770903.2014.887727

2014-01-01

Abstract:Objective: Bronchial asthma is a chronic inflammatory disease of the airway mediated by a Th2 immune response. A great deal of data has demonstrated that regulatory T cells (Tregs) have the ability to suppress Th2 immune responses and the transcription factor fork-head box protein 3 (Foxp3) is indispensable for the development of CD4 + CD25 + Tregs. In this study, we hypothesized that enhanced local Foxp3 expression in lung tissue could suppress Th2-mediated allergic asthma. Methods: Foxp3/PMX retroviruses containing the mouse Foxp3 gene were constructed and administered into asthmatic mice through intra-tracheal instillation before ovalbumin challenging. Foxp3 expression, airway hyper-responsiveness (AHR), bronchoalveolar lavage fluid (BALF) and tissue inflammatory cell and cytokine profiles were characterized. Results: Foxp3 mRNA and protein were increased in the lung tissue of asthmatic mice. Enhanced expression of Foxp3 locally in the lung tissue reduced the airway AHR, inflammatory cell infiltration and mucus production. It also attenuated Th2 and Th17 immune responses as evidenced by reduced IL-4, IL-13 and IL-17 levels. Conclusions: This study demonstrates that enhanced Foxp3 expression in the airway by intra-tracheally instilled Foxp3/ PMX retroviruses alleviates allergic airway inflammation by reducing the Th2 immune response.
The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

Li-yun SHI,Hong-ping YIN,Xie-lai ZHOU,feng XU,Jie YAN

DOI: https://doi.org/10.3321/j.issn:0254-5101.2008.06.003

2008-01-01

Abstract:Objective To determine the roles of thymic stromal lymphopoietin receptor (TSLPR) and its antibody in airway inflammatory response in asthmatic mice, and to promote maturation and activation of dendritic cells (DCs) in mouse airway. Methods BALB/c mice were randomly divided into group A, B and C. The mice in group B and C were intraperitoneally injected with OVA for allergization while the mice in group A were intraperitoneally injected with PBS as the normal control. The mice in group B and C were treated by inhalation of non-specific IgG and TSLPR IgG respectively, before provocation of asthma using OVA. The bronchoalveolar lavage fluid (BALF) of the mice in different groups were collected for cell differential counts and quantitative detection of IL-4, IL-5, IFN-γand IL-10 levels by ELISA. Moreover, the pulmonary tissue specimens of the mice were collected for pathological examination, and the numbers and phenotypes of DCs from the local lymph nodes and pulmonary tissue were determined by flow cytometry. Results The levels of all the tested cytokines in the BALF from mice in group B and C were remarkably higher compared to those from mice in group A (P<0.01). However, both the IL-4 and IL-5 levels in the BALF from group C mice that pre-blocked with TSLPR IgG were lower than those from group B (P<0.05, P<0.01), whereas both the IFN-γ and IL-10 levels in the BALF from group C mice were higher than those from group B (P<0.05, P<0.01). Furthermore, the numbers of total cells, eosinophils and lymphocytes in the BALF from group C mice were also lower than those from group B (P<0.01). A large number of inflammatory cell infiltration around the bronchus, beaker cell proliferation and mucous secretion reinforcement could be found in the samples from group B mice, while slight inflammatory cell infiltration and beaker cell proliferation in the samples from group C mice. The numbers of DCs in mediastinal lymph node and the levels of I-Ad, CD40, CD80 and CD86 expression of pulmonary DCs from group B mice were higher than those from group C mice (P<0.05). Conclusion TSLP/TSLPR have an effect on promoting asthma, which is closely relative to its regulation of DCs activation. And the interference of TSLPR antibody can decrease the effect of TSLP/TSLPR which indicating a potential of the antibody as a novel anti-asthma drug.
The effects of neutralizing anti-murine interleukin-17A monoclonal antibody on ozone-induced inflammation and glucocorticoids insensitivity in a murine model of asthma

Yingying Zhang,Xingjing Li,Mudan He,Guoqing Zhang,Wuping Bao,Xia Fei,Xue Zhang,Min Zhang,Pengyu Zhang

DOI: https://doi.org/10.1016/j.biopha.2019.108786

IF: 7.419

2019-01-01

Biomedicine & Pharmacotherapy

Abstract:Background and objective: Exposure to ozone contributed to the worsening of inflammation and glucocorticoids insensitivity in OVA-challenged asthma. Interleukin-17A participates centrally in stages of the inflammatory response and glucocorticoids insensitivity. In this study, the effect of neutralizing anti-murine interleukin-17A monoclonal antibody (IL-17A mAb) on inflammation and glucocorticoids insensitivity in ozone-exposed and ovalbumin (OVA)-challenged mice was investigated. Methods: Mice were sensitized and challenged with OVA and then exposed to ozone. Dexamethasone (Dex) and IL-17A mAb were administrated in corresponding periods. Results: Compared with OVA-challenged mice, combination administration of ozone exposure and OVA challenge increased the recruitment of inflammatory cells in bronchoalveolar lavage fluid, enhanced the inflammation scores and levels of inflammatory cytokines and IL-17A mRNA, and caused the activation of p38 MAPK together with down regulation of glucocorticoids recepters (GR) in lung tissue. Monotherapy of IL-17A mAb partially attenuated lung inflammation in OVA-challenged and ozone-exposed mice, while the combination treatment of Dex and IL-17A mAb effectively reduced lung inflammation, inactivated p38 MAPK and up regulated GR in lung tissue. Conclusions: Ozone exposure worsened OVA-challenged airway inflammation, activation of p38 MAPK and down regulation of GR in OVA-sensitized and -challenged mice, which was effectively counteracted by IL-17A mAb, and combination treatment of IL-17A mAb and Dex shows profound efficacy in inhibiting airway inflammation and improving glucocorticoids insensitivity synergistically.
VISTA: an Immune Regulatory Protein Checking Tumor and Immune Cells in Cancer Immunotherapy

Xing Huang,Xiaozhen Zhang,Enliang Li,Gang Zhang,Xun Wang,Tianyu Tang,Xueli Bai,Tingbo Liang

DOI: https://doi.org/10.1186/s13045-020-00917-y

IF: 28.5

2020-01-01

Journal of Hematology & Oncology

Abstract:VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized. Here, we review the current knowledge on the therapeutic phenotypes and molecular mechanisms that underlie the contradictory roles of VISTA in checking anti-cancer immune responses. Furthermore, we highlight the potential indeterminacy of VISTA-targeted strategies in cancer immunotherapy, with in silico analyses. In fact, VISTA functions like a homeostatic regulator that actively normalizes immune responses. Thus, the regulatory role of VISTA in anti-cancer immunity remains to be fully elucidated.
Vitamin D has an effect on airway inflammation and Th17/Treg balance in asthmatic mice

Jing-Guo Ma,Guang-Ji Wu,Hong-Li Xiao,Yan-Min Xiao,Lin Zha

DOI: https://doi.org/10.1002/kjm2.12441

Abstract:Asthma is regarded as a chronic inflammation of the airway. Research has highlighted the significance of Vitamin D in asthma. This study explored the mechanism of vitamin D on asthma. The asthma mouse model was established by ovalbumin (OVA) sensitization and treated with vitamin D (50 or 100 ng/ml). The morphological changes of the airway were observed by HE staining. The serum IgE contents and MDA, ROS, and SOD expressions in the bronchoalveolar lavage fluid (BALF) were detected by ELISA. The Th17 and Treg cells were detected using flow cytometry. The RORγt and Foxp 3 expressions were detected by Reverse transcription quantitative polymerase chain reaction (RT-qPCR). IL-17, IL-10, and TGF-β1 expressions were detected using ELISA. The NF-κB pathway was blocked using the NF-κB pathway inhibitor, Andrographolide sulfonate. The NF-κB pathway-related indexes were detected by western blotting. After blockade of the NF-κB pathway, the IL-17, IL-10, and TGF-G1 expressions were detected. OVA-sensitized asthma induced airway remodeling and elevated IgE content in mice, which was downregulated after vitamin D treatment. MDA and ROS were upregulated and SOD was downregulated in asthmatic mice, while vitamin D inverted the changes. Th17/Treg ratio was imbalanced, RORγt and IL-17 were upregulated, and Foxp 3, IL-10, and TGF-β1 were downregulated after OVA sensitization, while vitamin D treatment inverted these changes and inhibited the NF-κB-p65 phosphorylation level. After blockade of the NF-κB pathway, IL-17 was downregulated and IL-10 and TGF-β1 were upregulated. In conclusion, vitamin D rectified the Th17/Treg balance and alleviated airway inflammation by inhibiting the NF-κB pathway in asthmatic mice.
Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection

Meijun Zheng,Zongliang Zhang,Lingyu Yu,Zeng Wang,Yijun Dong,Aiping Tong,Hui Yang

DOI: https://doi.org/10.3389/fimmu.2023.1194421

IF: 7.3

2023-06-26

Frontiers in Immunology

Abstract:Negative checkpoint regulators (NCRs) reduce the T cell immune response against self-antigens and limit autoimmune disease development. V-domain Ig suppressor of T cell activation (VISTA), a novel immune checkpoint in the B7 family, has recently been identified as one of the NCRs. VISTA maintains T cell quiescence and peripheral tolerance. VISTA targeting has shown promising results in treating immune-related diseases, including cancer and autoimmune disease. In this review, we summarize and discuss the immunomodulatory role of VISTA, its therapeutic potential in allergic, autoimmune disease, and transplant rejection, as well as the current therapeutic antibodies, to present a new method for regulating immune responses and achieving durable tolerance for the treatment of autoimmune disease and transplantation.

immunology
VISTA Deficiency Exacerbates the Development of Pulmonary Fibrosis by Promoting Th17 Differentiation

Haiping Xie,Xuexin Zhong,Junlin Chen,Shuang Wang,Yuefang Huang,Niansheng Yang

DOI: https://doi.org/10.2147/jir.s458651

IF: 4.5

2024-06-20

Journal of Inflammation Research

Abstract:Haiping Xie, 1, &ast Xuexin Zhong, 1, &ast Junlin Chen, 2 Shuang Wang, 1 Yuefang Huang, 2 Niansheng Yang 1 1 Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, People's Republic of China; 2 Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, People's Republic of China &astThese authors contributed equally to this work Correspondence: Niansheng Yang, Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China, Tel +86-20-87755766 ext 8150, Email Background: Interstitial lung disease (ILD), characterized by pulmonary fibrosis (PF), represents the end-stage of various ILDs. The immune system plays an important role in the pathogenesis of PF. V-domain immunoglobulin suppressor of T-cell activation (VISTA) is an immune checkpoint with immune suppressive functions. However, its specific role in the development of PF and the underlying mechanisms remain to be elucidated. Methods: We assessed the expression of VISTA in CD4 T cells from patients with connective tissue disease-related interstitial lung disease (CTD-ILD). Spleen cells from wild-type (WT) or Vsir −/− mice were isolated and induced for cell differentiation in vitro. Additionally, primary lung fibroblasts were isolated and treated with interleukin-17A (IL-17A). Mice were challenged with bleomycin (BLM) following VISTA blockade or Vsir knockout. Moreover, WT or Vsir −/− CD4 T cells were transferred into Rag1 −/− mice, which were then challenged with BLM. Results: VISTA expression was decreased in CD4 T cells from patients with CTD-ILD. Vsir deficiency augmented T-helper 17 (Th17) cell differentiation in vitro. Furthermore, IL-17A enhanced the production of inflammatory cytokines, as well as the differentiation and migration of lung fibroblasts. Both VISTA blockade and knockout of Vsir increased the percentage of IL-17A-producing Th17 cells and promoted BLM-induced PF. In addition, mice receiving Vsir −/− CD4 T cells exhibited a higher percentage of Th17 cells and more severe PF compared to those receiving WT CD4 T cells. Conclusion: These findings demonstrate the significant role of VISTA in modulating the development of PF by controlling Th17 cell differentiation. These insights suggest that targeting VISTA could be a promising therapeutic strategy for PF. Keywords: VISTA, lung fibrosis, Th17 cells, IL-17A, fibroblast Graphical Interstitial lung disease (ILD) is characterized by the involvement of lung interstitium and alveolar spaces, presenting with abnormal proliferation of alveolar wall cells, infiltration of inflammatory cells, and interstitial fibrosis. 1 Pulmonary fibrosis (PF) represents the end-stage of various ILDs, characterized by fibroblast activation, progressive synthesis and deposition of extracellular matrix (ECM), ultimately leading to the destruction of lung architecture. 2 Despite this understanding, the precise mechanisms underlying PF remain unclear. Therefore, a more thorough exploration of PF pathogenesis may reveal novel therapeutic targets for anti-fibrotic treatment. Recently, researchers have uncovered various functions of profibrotic cytokines in the pathogenesis of PF. Interleukin-17A (IL-17A) secreted by T-helper 17 (Th17) cells has been identified as a key promoter of PF development. 3–6 The frequency of IL-17A + CD4 + T cells is expanded in ILD patients. 7,8 In Bleomycin (BLM)-induced PF, IL-17A has been found to enhance neutrophil accumulation and exacerbate PF progression. Conversely, blockade of IL-17A has been shown to alleviate lung inflammation and fibrosis. 6,9,10 Additionally, research has demonstrated that IL-17A enhances collagen synthesis and secretion, promotes epithelial–mesenchymal transition, and suppresses epithelial cell autophagy, all contributing to the exacerbation of PF. 11 Despite these findings, the molecules and specific mechanisms regulating IL-17A secretion by Th17 cells in the context of PF remain elusive, highlighting the need for further research. T cells are involved in PF by secreting numerous profibrotic and inflammatory cytokines, contributing to the subsequent process of fibroblast activation and ECM deposition. 12–14 Immune checkpoints such as PD-1, TIGIT and LAG3 are known to regulate the activation, differentiation and cytokine secretio -Abstract Truncated-

immunology
Low Doses Of Exogenous Interferon-Gamma Attenuated Airway Inflammation Through Enhancing Fas/Fasl-Induced Cd4(+) T Cell Apoptosis In A Mouse Asthma Model

Yinan Yao,Shan Lu,Hequan Li,Guohua Lu,Jianying Zhou

DOI: https://doi.org/10.1089/jir.2012.0016

2012-01-01

Abstract:To investigate whether low doses of exogenous interferon (IFN)-gamma attenuate airway inflammation, and the underlying mechanisms, in asthma. C57BL/6 mice (n = 42), after intraperitoneal ovalbumin (OVA) sensitization on day 0 and day 12, were challenged with OVA aerosol for 6 consecutive days. Different doses of IFN-gamma were then administered intraperitoneally 5 min before each inhalation during OVA challenge. Airway hyperresponsiveness, airway inflammatory cells, cytokine profiles, and Fas/FasL expression on CD4(+) T cells were evaluated in an asthma model. The effect of various IFN-gamma doses on Fas/FasL expression and CD4(+) T cell apoptosis were assessed in vitro. We demonstrated that low doses of IFN-gamma reduced pulmonary infiltration of inflammatory cells, Th2 cytokine production, and goblet cells hyperplasia (P < 0.05), while high doses of endogenous IFN-gamma had almost no effect. We also found that low doses of IFN-gamma relocated Fas/FasL to the CD4(+) T cell surface in the asthma model (P < 0.05) and increased FasL-induced apoptosis in vitro (P < 0.05). Furthermore, treatment with MFL-3, an anti-FasL antibody, partially abolished the anti-inflammatory properties of IFN-gamma in the airway rather than affecting the Th1/Th2 balance. This research has revealed an alternative mechanism in asthma that involves low doses of IFN-gamma, which attenuate airway inflammation through enhancing Fas/FasL-induced CD4(+) T cell apoptosis.
STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration

Yishu Xue,Yan Zhou,Wuping Bao,Qiang Fu,Huijuan Hao,Lei Han,Xue Zhang,Xue Tian,Min Zhang

DOI: https://doi.org/10.3389/fmolb.2021.717962

IF: 6.113

2021-01-01

Frontiers in Molecular Biosciences

Abstract:Exposure to high levels of ozone contributes to insensitivity to glucocorticoids in asthma treatment, but the underlying mechanisms are not known. We built two asthma models: a "T2-high" asthma model was established by ovalbumin (OVA) sensitization/challenge and OVA sensitization/challenge combined with ozone exposure (OVA + ozone) was used to induce airway inflammation with increased numbers of neutrophils to simulate "T2-low" asthma. The expression of T-helper (Th)1/2/17-related cytokines was measured by cytokine antibody arrays. Bronchial provocation tests were carried out to evaluate the lung resistance of mice. Hematoxylin and eosin staining, periodic acid-Schiff staining, and immunohistochemical (IHC) analyses of alpha-smooth muscle actin were undertaken to observe morphology changes in lungs. The expression of glucocorticoid receptors (GRs) and phosphorylated-GR (p-GR) was measured by western blotting. Nr3c1 mRNA was quantified by RT-qPCR. Protein expression of proinflammatory cytokines, signal transducer and activator of transcription 3 (STAT3), suppressor of cytokine signaling 3 (SOCS3), and CXCL1 was measured through ELISAs, western blotting, or IHC analyses. Resected lung tissue from seven asthma patients and 10 healthy controls undergoing thoracotomy for pulmonary nodules was evaluated by IHC analyses and ELISAs. In both asthma models, mucus hypersecretion, as well as inflammation, hyperresponsiveness, and remodeling of the airways, was present compared with the control group, whereas the OVA + ozone group showed severe neutrophil infiltration. The expression of Th17-related cytokines (interleukin (IL)-6, IL-17A, IL-21), GR protein, and CXCL1 increased in the OVA + ozone group, whereas the expression of p-GR decreased. Dexamethasone (Dex) could not totally reverse the expression of p-GR and histone deacetylase-2 in the OVA + ozone group. STAT3 expression increased in the OVA + ozone group and could not be completely reversed by Dex, and nor could IL-6 expression. A positive correlation between IL-6 or IL-17A and STAT3 and negative correlation between SOCS3 and STAT3 were shown, suggesting that the IL-6/STAT3 pathway may be involved in OVA + ozone-induced corticosteroid-resistant airway inflammation. In clinical samples, IL-17A expression in lung tissue was positively correlated with percent STAT3-positive area and negatively correlated with SOCS3 expression. The IL-6/STAT3 pathway may contribute to corticosteroid insensitivity in OVA + ozone-induced neutrophilic airway inflammation through regulation of Th17 cells and could provide new targets for individual treatment of corticosteroid resistance in asthma.
VISTA Inhibitors in Cancer Immunotherapy: a Short Perspective on Recent Progresses.

Chenyang Wu,Xin Cao,Xiaojin Zhang

DOI: https://doi.org/10.1039/d1md00185j

2021-01-01

RSC Medicinal Chemistry

Abstract:V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is a novel negative checkpoint regulator that mediates T cell proliferation and cytokine production. The VISTA signaling pathway blockade has been proved as a promising strategy for cancer immunotherapy. Recent VISTA sequence analysis and crystal structure investigations have revealed its independent and unique function as compared with B7 family members, such as PD-1. This review will discuss VISTA binding partners and compare the structural differences between VISTA and other B7 family members, focusing on VISTA functions in immune activation and maintaining T cell quiescence. Recent progress and the therapeutic potential of biomacromolecules, such as monoclonal antibodies (mAbs) and small molecules targeting VISTA, are also discussed. Among these, a first-in-class small-molecule antagonist, CA-170, is highlighted.
VISTA-Ig ameliorates OXA-induced allergic dermatitis symptoms in mice

Yuying Guo,Cong Ding,Tao Chang,Weitang Yuan,Xin Liu

DOI: https://doi.org/10.1080/08923973.2021.1925907

IF: 3.712

2021-05-04

Immunopharmacology and Immunotoxicology

Abstract:<span>Allergic dermatitis (AD) is a chronic inflammatory skin disease that a variety of immune cells are involved in the progression of AD. Among them, T cells are one of major players of AD pathogenesis. The V-domain Ig suppressor of T cell activation (VISTA) has been reported that it has a potential immunomodulatory for T cell response.This study aimed to investigate immunomodulatory of recombinant VISTA-Ig fusion protein in AD mice model.The model of AD was built with oxazolone (OXA) in BALB/c mice, then VISTA-Ig was used to treat AD by intraperitoneal (IP) injection. The ear thickness was measured by a digital thickness gauge. The ears tissues were collected and subjected to hematoxylin-eosin (H&E) and toluidine blue (TB) staining. The secretion levels of IL-4 and IgE in the serum were measured by enzyme linked immunosorbent assay (ELISA). The mRNA expression levels of inflammatory cytokines (IL-1β, IL-6, IL-12, and INF-γ) in ear tissues were measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).Treatment with VISTA-Ig successfully alleviated the symptoms of AD, such as erythema, horny substance, and swelling. The infiltration of inflammatory cells was significantly reduced following VISTA-Ig therapy. The secretion levels of IL-4 and IgE in the serum were significantly attenuated following treatment with VISTA-Ig. Additionally, VISTA-Ig observably down-regulated inflammatory cytokines expression in ear tissues.Taken together, our results showed that VISTA-Ig possessed the potential to be a novel immunomodulatory candidate drug against AD.</span>

pharmacology & pharmacy,immunology,toxicology
Exposure to Ozone Impacted Th1/Th2 Imbalance of CD4+ T Cells and Apoptosis of ASMCs Underlying Asthmatic Progression by Activating Lncrna PVT1-miR-15a-5p/miR-29c-3p Signaling

Yangyang Wei,Baofen Han,Wenjuan Dai,Shufang Guo,Caiping Zhang,Lixuan Zhao,Yan Gao,Yi Jiang,Xiaomei Kong

DOI: https://doi.org/10.18632/aging.104124

2020-01-01

Aging

Abstract:This investigation attempted to elucidate whether lncRNA PVT1-led miRNA axes participated in aggravating ozone-triggered asthma progression. One hundred and sixty-eight BALB/c mice were evenly divided into saline+air group, ovalbumin+air group, saline+ozone group and ovalbumin+ozone group. Correlations were evaluated between PVT1 expression and airway smooth muscle function/inflammatory cytokine release among the mice models. Furthermore, pcDNA3.1-PVT1 and si-PVT1 were, respectively, transfected into CD4+T cells and airway smooth muscle cells (ASMCs), and activities of the cells were observed. Ultimately, a cohort of asthma patients was recruited to estimate the diagnostic performance of PVT1. It was demonstrated that mice of ovalbumin+ozone group were associated with higher PVT1 expression, thicker trachea/airway smooth muscle and smaller ratio of Th1/Th2-like cytokines than mice of ovalbumin+air group and saline+ozone group (P<0.05). Moreover, pcDNA3.1-PVT1 significantly brought down Th1/Th2 ratio in CD4+ T cells by depressing miR-15a-5p expression and activating PI3K-Akt-mTOR signaling (P<0.05). The PVT1 also facilitated ASMC proliferation by sponging miR-29c-3p and motivating PI3K-Akt-mTOR signaling (P<0.05). Additionally, PVT1 seemed promising in diagnosis of asthma, with favorable sensitivity (i.e. 0.844) and specificity (i.e. 0.978). Conclusively, lncRNA PVT1-miR-15a-5p/miR-29c-3p-PI3K-Akt-mTOR axis was implicated in ozone-induced asthma development by promoting ASMC proliferation and Th1/Th2 imbalance.
Regulation of Th17/Treg Function Contributes to the Attenuation of Chronic Airway Inflammation by Icariin in Ovalbumin-Induced Murine Asthma Model.

Ying Wei,Baojun Liu,Jing Sun,Yubao Lv,Qingli Luo,Feng Liu,Jingcheng Dong

DOI: https://doi.org/10.1016/j.imbio.2014.12.015

IF: 3.152

2015-01-01

Immunobiology

Abstract:Icariin which is a flavonoid glucoside isolated from Epimedium brevicornu Maxim, has been reported to have anti-osteoporotic, anti-inflammatory and anti-depressant-like activities. In this study, we observed the effect of icariin on airway inflammation of ovalbumin (OVA)-induced murine asthma model and the associated regulatory mode on T-helper (Th)17 and regulatory T (Treg) cell function. Our data revealed that chronic OVA inhalation induced a dramatic increase in airway resistance (RL) and decrease in the lung dynamic compliance (Cdyn), and icariin and DEX treatment caused significant attenuation of such airway hyperresponsiveness (AHR). BALF cell counts demonstrated that icariin and DEX led to a prominent reduction in total leukocyte as well as lymphocyte, eosinophil, neutrophil, basophil and monocyte counts. Histological analysis results indicated that icariin and DEX alleviated the inflammatory cells infiltrating into the peribronchial tissues and goblet cells hyperplasia and mucus hyper-production. Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORγt+ T cells and elevation of CD4+Foxp3+ T cells in BALF. Furthermore, icariin or DEX caused a significant reduction in IL-6, IL-17 and TGF-β level in BALF. Unfortunately, icariin had no effect on IL-10 level in BALF. Western blot assay found that icariin or DEX suppressed RORγt and promoted Foxp3 expression in the lung tissue. qPCR analysis revealed that icariin and DEX resulted in a notable decrease in RORγt and increase in Foxp3 mRNA expression in isolated spleen CD4+ T cell. In conclusion, our results suggested that icariin was effective in the attenuation of AHR and chronic airway inflammatory changes in OVA-induced murine asthma model, and this effect was associated with regulation of Th17/Treg responses, which indicated that icariin may be used as a potential therapeutic method to treat asthma with Th17/Treg imbalance phenotype.
VISTA: A Target to Manage the Innate Cytokine Storm

Mohamed A. ElTanbouly,Yanding Zhao,Evelien Schaafsma,Christopher M. Burns,Rodwell Mabaera,Chao Cheng,Randolph J. Noelle

DOI: https://doi.org/10.3389/fimmu.2020.595950

IF: 7.3

2021-02-11

Frontiers in Immunology

Abstract:In recent years, the success of immunotherapy targeting immunoregulatory receptors (immune checkpoints) in cancer have generated enthusiastic support to target these receptors in a wide range of other immune related diseases. While the overwhelming focus has been on blockade of these inhibitory pathways to augment immunity, agonistic triggering via these receptors offers the promise of dampening pathogenic inflammatory responses. V-domain Ig suppressor of T cell activation (VISTA) has emerged as an immunoregulatory receptor with constitutive expression on both the T cell and myeloid compartments, and whose agonistic targeting has proven a unique avenue relative to other checkpoint pathways to suppress pathologies mediated by the innate arm of the immune system. VISTA agonistic targeting profoundly changes the phenotype of human monocytes towards an anti-inflammatory cell state, as highlighted by striking suppression of the canonical markers CD14 and Fcγr3a (CD16), and the almost complete suppression of both the interferon I (IFN-I) and antigen presentation pathways. The insights from these very recent studies highlight the impact of VISTA agonistic targeting of myeloid cells, and its potential therapeutic implications in the settings of hyperinflammatory responses such as cytokine storms, driven by dysregulated immune responses to viral infections (with a focus on COVID-19) and autoimmune diseases. Collectively, these findings suggest that the VISTA pathway plays a conserved, non-redundant role in myeloid cell function.

immunology
Fusion protein mTSLPR-Ig regulates CD11c~+ cells and improve the inflammatory reactions in a mouse model of asthma

ZHANG Fang,SHI Yi,LI Zi-ling,HU Bo,SONG Yong

2011-01-01

Abstract:Thymic stromal lymphopoietin(TSLP) activates CD11c+ through the combination with its receptor(TSLPR) on the surface of CD11c+,thus resulting in Th1/Th2 imbalance in asthma.To study the feasibility of fusion protein mTSLPR-Ig constituted by the extracellular segment of mouse TSLPR and mouse Fc of Ig,to reverse Th1/Th2 imbalance and to improve airway inflammation in asthma mouse in order to explore the mechanism of mTSLPR-Ig inducing immune tolerance in asthma by regulating CD11c+,ovalbumin(OVA) was injected intraperitoneally and challenged with aerosol inhalation in BALB/c mice to establish an animal models of asthma.Before the OVA challenging,mTSLPR-Ig were infused intranasally in mice.The total number of cells in BALF,eosinophils and lymphocytes were counted with light microscope,and the levels of cytokines IL-4,IL-5,IFN-γ and IL-10 in BALF were evaluated with ELISA assay.The inflammatory reactions of lung was observed with HE staining.After the preparation of lungs tissues into cell suspension,the expression of co-stimulatory molecules CD80,CD86 and CD40 on the surface of CD11c+ were detected with FCM assay.It was demonstrated that the airway inflammation,the counts of total cell and eosinophil,and IL-4,IL-5 level in BALF were significantly reduced in mTSLPR-Ig treated mice,while IL-10,IFN-γ level were enhanced.TSLPR-mIg treatment resulted in the reduction of CD80,CD86 and CD40 expression significantly.From these observation,it is evident that mTSLPR-Ig can inhibit allergic lung inflammation and Th1/Th2 imbalance,which may be related to the expression suppression of the co-stimulatory molecules on pulmonary CD11c+ by fusion protein mTSLPR-Ig,indicating that this fusion protein may have potential clinical value for the treatment of asthma,and providing a new way to treat this allergic disease.
VISTA Blockade Aggravates Bone Loss in Experimental Murine Apical Periodontitis

Fuhua Yang,Yifei Zhang,Zhi Chen,Lu Zhang

DOI: https://doi.org/10.3389/fimmu.2021.738586

IF: 7.3

2021-10-07

Frontiers in Immunology

Abstract:V-domain Ig suppressor of T cell activation (VISTA) is a novel coinhibitory immune checkpoint molecule that maintains immune homeostasis. The present study explored the role of VISTA in human and murine inflammatory tissues of apical periodontitis (AP). VISTA was upregulated in inflammatory tissues of human AP. In mice, the expression of VISTA gradually increased with the development of mouse experimental apical periodontitis (MAP), the CD3 + T cells, CD11b + myeloid cells, and FOXP3 + regulatory T cells also gradually accumulated. Moreover, a blockade of VISTA using a mouse in vivo anti-VISTA antibody aggravated periapical bone loss and enhanced the infiltration of immune cells in an experimental mouse periapical periodontitis model. The collective results suggest that VISTA serves as a negative regulator of the development and bone loss of apical periodontitis.

immunology
The role of VISTA engagement in limiting neutrophil-mediated inflammation

Elizabeth C. Nowak,Jiannan Li,Mohamed A. ElTanbouly,Wilson L. Davis III,Petra Sergent,Lindsay K. Mendyka,J. Louise Lines,Nicole C. Smits,Rodwell Mabaera,Shibani Rajanna,Catherine Carriere,Brent Koehn,Bruce R. Blazar,Christopher M. Burns,Randolph J. Noelle,Sladjana Skopelja-Gardner

DOI: https://doi.org/10.1101/2024.05.05.592601

2024-05-05

Abstract:A growing body of evidence suggests that VISTA, an immune checkpoint inhibitory receptor, plays a central role in the regulation of innate immunity in the settings of inflammatory diseases and cancer. Neutrophils are among the cells that have the highest membrane density of surface VISTA. Targeting VISTA on neutrophils with an agonist antibody resulted in a striking reduction in their LPS-induced peripheral accumulation. Fc receptor engagement was required for anti-VISTA antibody to mediate its effects on neutrophils. Concomitant with reduced peripheral neutrophil cell numbers, anti-VISTA antibody treatment increased neutrophil cell death in the liver. In a murine model of neutrophil-mediated arthritis, agonist anti-VISTA antibody treatment ameliorated disease severity, which was associated with reduced myeloperoxidase activity in the joints. These studies add to a growing spectrum of negative regulatory functions that VISTA performs in controlling inflammation through the innate and adaptive arms of the immune system that has implications for translation into the clinic.

Immunology

Localization of aromatase and 5α-reductase to neuronal and non-neuronal cells in the fetal rat hypothalamus

Fc Gamma Riiia Negatively Impacts Humoral Immune Responses But Not Overall Lung Inflammation In An Ovalbumin-Induced Allergic Asthma Mouse Model

Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma

Enhanced Local Foxp3 Expression in Lung Tissue Attenuates Airway Inflammation in A Mouse Model of Asthma

The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

The effects of neutralizing anti-murine interleukin-17A monoclonal antibody on ozone-induced inflammation and glucocorticoids insensitivity in a murine model of asthma

VISTA: an Immune Regulatory Protein Checking Tumor and Immune Cells in Cancer Immunotherapy

Vitamin D has an effect on airway inflammation and Th17/Treg balance in asthmatic mice

Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection

VISTA Deficiency Exacerbates the Development of Pulmonary Fibrosis by Promoting Th17 Differentiation

Low Doses Of Exogenous Interferon-Gamma Attenuated Airway Inflammation Through Enhancing Fas/Fasl-Induced Cd4(+) T Cell Apoptosis In A Mouse Asthma Model

STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration

VISTA Inhibitors in Cancer Immunotherapy: a Short Perspective on Recent Progresses.

VISTA-Ig ameliorates OXA-induced allergic dermatitis symptoms in mice

Exposure to Ozone Impacted Th1/Th2 Imbalance of CD4+ T Cells and Apoptosis of ASMCs Underlying Asthmatic Progression by Activating Lncrna PVT1-miR-15a-5p/miR-29c-3p Signaling

Regulation of Th17/Treg Function Contributes to the Attenuation of Chronic Airway Inflammation by Icariin in Ovalbumin-Induced Murine Asthma Model.

VISTA: A Target to Manage the Innate Cytokine Storm

Fusion protein mTSLPR-Ig regulates CD11c~+ cells and improve the inflammatory reactions in a mouse model of asthma

VISTA Blockade Aggravates Bone Loss in Experimental Murine Apical Periodontitis

The role of VISTA engagement in limiting neutrophil-mediated inflammation